All In Biotech

NDA 017874 · Baxter Hlthcare Corp

Transderm Scop

Scopolamine · Transdermal · Anticholinergic

Last checked: Nov 20, 2026Latest source record: Jun 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1979

Dec 31, 1979

Approved uses

2

Original approval plus efficacy supplements

Registered trials

387

119 Phase 3, 9 recruiting

FAERS reports

5,759

3,941 serious, 765 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 10, 2025.

TRANSDERM SCŌP is indicated in adults for the prevention of: • nausea and vomiting associated with motion sickness. • post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. TRANSDERM SCŌP is an anticholinergic indicated in adults for the prevention of: • nausea and vomiting associated with motion sickness. ( 1 ) • post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. ( 1 )

Mechanism: Scopolamine, a belladonna alkaloid, is an anticholinergic. Scopolamine acts: i) as a competitive inhibitor at postganglionic muscarinic receptor sites of the parasympathetic nervous system, and ii) on smooth muscles that respond to acetylcholine but lack cholinergic innervation. It has been suggested that scopolamine acts in the central nervous system (CNS) by blocking cholinergic transmission from the vestibular nuclei to higher centers in the CNS and from the reticular formation to the vomiting center. Scopolamine can inhibit the secretion of saliva and sweat, decrease gastrointestinal...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 1, 2019 Supplement 43 · Efficacy LabelLetter
  • Dec 31, 1979 Original approval · Type 3 - New Dosage Form
1 products under this application
  • TRANSDERM SCOP · SCOPOLAMINE 1MG/72HR · SYSTEM, TRANSDERMAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Scopolamine" as an intervention, any sponsor and status, largest first.

All 387 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea711
  • off label use609
  • vomiting501
  • dizziness454
  • headache366
  • drug ineffective346
  • fatigue300
  • vision blurred279
  • death257
  • diarrhoea252
  • malaise252
  • confusional state243

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200432
200548
200660
200751
200892
200985
2010118
2011262
2012248
2013135
2014143
2015169
2016539
2017408
2018370
2019356
2020221
2021309
2022510
2023483
2024403
2025394
2026322

Recalls

1 FDA enforcement reports for this application.

  • Apr 13, 2022 · Class II · Terminated

    cGMP deviations: Temperature abuse

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Transderm-Scop (Scopolamine)

2024 spending

$291K

Beneficiaries

768

1,636 claims

Per beneficiary

$378

$19.96 per unit

View as table
YearSpending
2020$2,262,354
2021$1,002,465
2022$443,626
2023$347,632
2024$290,661

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 504 on PubMed

Sponsor: Baxter Hlthcare Corp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.